Oct. 18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa). This new option is designed to help people ...

AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...

The treatment allows patients to have a steady flow of dopamine that is needed to cope with the tremors, stiffness and slow movement that often comes with Parkinson’s disease.

The Food and Drug Administration approved a drug produced by AbbVie for the treatment of late stage Parkinsons disease the company announced Thursday. The regulator approved Vyalev, also known as ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...

Clinical studies have revealed that rasagiline is associated with improved outcomes in patients with early Parkinson's disease (PD ... may be more prone to treatment-emergent adverse ...

Veterans were included if they had Parkinson’s disease based on ≥ 1 ICD code and confirmed by symptoms and medication for Parkinson’s disease documented in the electronic medical record (EMR).

Parkinson's disease and attention deficit hyperactivity ... consortium—an international effort led by Keck School of Medicine, USC—as well as from Cohorts for Heart and Aging Research in ...

for adults living with advanced Parkinson's disease (PD). Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in ...